A BILL 
To amend the Federal Trade Commission Act to prohibit 
anticompetitive behaviors by drug product manufactur-
ers, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable Prescrip-
4
tions for Patients Through Promoting Competition Act of 
5
2019’’. 
6
SEC. 2. PRODUCT HOPPING. 
7
(a) IN GENERAL.—The Federal Trade Commission 
8
Act (15 U.S.C. 41 et seq.) is amended by inserting after 
9
section 26 (15 U.S.C. 57c–2) the following: 
10
21:44 Sep 20, 2019
H4398
2 
•HR 4398 IH
‘‘SEC. 27. PRODUCT HOPPING. 
1
‘‘(a) DEFINITIONS.—In this section: 
2
‘‘(1) ABBREVIATED NEW DRUG APPLICATION.— 
3
The term ‘abbreviated new drug application’ means 
4
an application under subsection (b)(2) or (j) of sec-
5
tion 505 of the Federal Food, Drug, and Cosmetic 
6
Act (21 U.S.C. 355). 
7
‘‘(2) BIOSIMILAR BIOLOGICAL PRODUCT.—The 
8
term ‘biosimilar biological product’ means a biologi-
9
cal product licensed under section 351(k) of the 
10
Public Health Service Act (42 U.S.C. 262(k)). 
11
‘‘(3) BIOSIMILAR
BIOLOGICAL
PRODUCT
LI-
12
CENSE APPLICATION.—The term ‘biosimilar biologi-
13
cal product license application’ means an application 
14
submitted under section 351(k) of the Public Health 
15
Service Act (42 U.S.C. 262(k)). 
16
‘‘(4) FOLLOW-ON PRODUCT.—The term ‘follow- 
17
on product’— 
18
‘‘(A) means a drug approved through an 
19
application or supplement to an application sub-
20
mitted under section 505(b) of the Federal 
21
Food, Drug, and Cosmetic Act (21 U.S.C. 
22
355(c)) or a biological product licensed through 
23
an application or supplement to an application 
24
submitted under section 351(a) of the Public 
25
Health Service Act (42 U.S.C. 262(a)) for a 
26
21:44 Sep 20, 2019
H4398
3 
•HR 4398 IH
change, modification, or reformulation to the 
1
same manufacturer’s previously approved drug 
2
or biological product that treats the same med-
3
ical condition; and 
4
‘‘(B) excludes such an application or sup-
5
plement to an application for a change, modi-
6
fication, or reformulation of a drug or biological 
7
product that is requested by the Secretary or 
8
necessary to comply with law, including sections 
9
505A and 505B of the Federal Food, Drug, 
10
and Cosmetic Act (21 U.S.C. 355a, 355c). 
11
‘‘(5) GENERIC DRUG.—The term ‘generic drug’ 
12
means a drug approved under an application sub-
13
mitted under subsection (b)(2) or (j) of section 505 
14
of the Federal Food, Drug, and Cosmetic Act (21 
15
U.S.C. 355). 
16
‘‘(6) LISTED
DRUG.—The term ‘listed drug’ 
17
means a drug listed under section 505(j)(7) of the 
18
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
19
355(j)(7)). 
20
‘‘(7) MANUFACTURER.—The term ‘manufac-
21
turer’ means the holder, licensee, or assignee of— 
22
‘‘(A) an approved application for a drug 
23
under section 505(c) of the Federal Food, 
24
Drug, and Cosmetic Act (21 U.S.C. 355(c)); or 
25
21:44 Sep 20, 2019
H4398
4 
•HR 4398 IH
‘‘(B) a biological product license under sec-
1
tion 351(a) of the Public Health Service Act 
2
(42 U.S.C. 262(a)). 
3
‘‘(8) REFERENCE
PRODUCT.—The term ‘ref-
4
erence product’ has the meaning given the term in 
5
section 351(i) of the Public Health Service Act (42 
6
U.S.C. 262(i)). 
7
‘‘(9) ULTIMATE
PARENT
ENTITY.—The term 
8
‘ultimate parent entity’ has the meaning given the 
9
term in section 801.1 of title 16, Code of Federal 
10
Regulations, or any successor regulation. 
11
‘‘(b) PROHIBITION ON PRODUCT HOPPING.— 
12
‘‘(1) PRIMA
FACIE.—Except as provided in 
13
paragraph (2), a manufacturer of a reference prod-
14
uct or listed drug shall be considered to have en-
15
gaged in an unfair method of competition in or af-
16
fecting commerce in violation of section 5(a) if the 
17
Commission demonstrates by a preponderance of the 
18
evidence in a proceeding initiated by the Commission 
19
under subsection (c)(1)(A), or in a suit brought 
20
under subparagraph (B) or (C) of subsection (c)(1), 
21
that, during the period beginning on the date on 
22
which the manufacturer of the reference product or 
23
listed drug first receives notice that an applicant has 
24
submitted to the Commissioner of Food and Drugs 
25
21:44 Sep 20, 2019
H4398
5 
•HR 4398 IH
an abbreviated new drug application or biosimilar bi-
1
ological product license application and ending on 
2
the date that is 180 days after the date on which 
3
that generic drug or biosimilar biological product is 
4
first marketed, the manufacturer engaged in either 
5
of the following actions: 
6
‘‘(A) The manufacturer engaged in a hard 
7
switch, which shall be established by dem-
8
onstrating that the manufacturer engaged in ei-
9
ther of the following actions: 
10
‘‘(i) Upon the request of the manufac-
11
turer of the listed drug or reference prod-
12
uct, the Commissioner of Food and Drugs 
13
withdrew the approval of the application 
14
for the listed drug or reference product or 
15
placed the listed drug or reference product 
16
on the discontinued products list and the 
17
manufacturer marketed or sold a follow-on 
18
product. 
19
‘‘(ii)(I) The manufacturer of the listed 
20
drug or reference product— 
21
‘‘(aa) announced withdrawal of, 
22
discontinuance of the manufacture of, 
23
or intent to withdraw the application 
24
with respect to the drug or reference 
25
21:44 Sep 20, 2019
H4398
6 
•HR 4398 IH
product in a manner that impedes 
1
competition from a generic drug or a 
2
biosimilar biological product, as estab-
3
lished by objective circumstances; or 
4
‘‘(bb) destroyed the inventory of 
5
the listed drug or reference product in 
6
a manner that impedes competition 
7
from a generic drug or a biosimilar bi-
8
ological product, which may be estab-
9
lished by objective circumstances; and 
10
‘‘(II) marketed or sold a follow-on 
11
product. 
12
‘‘(B) The manufacturer engaged in a soft 
13
switch, which shall be established by dem-
14
onstrating that the manufacturer engaged in 
15
both of the following actions: 
16
‘‘(i) The manufacturer took actions 
17
with respect to the listed drug or reference 
18
product other than those described in sub-
19
paragraph (A) that unfairly disadvantage 
20
the listed drug or reference product rel-
21
ative to the follow-on product described in 
22
clause (ii) in a manner that impedes com-
23
petition from a generic drug or a bio-
24
similar biological product that is highly 
25
21:44 Sep 20, 2019
H4398
7 
•HR 4398 IH
similar to, and has no clinically meaningful 
1
difference with respect to safety, purity, 
2
and potency from, the reference product, 
3
which may be established by objective cir-
4
cumstances. 
5
‘‘(ii) The manufacturer marketed or 
6
sold a follow-on product. 
7
‘‘(2) JUSTIFICATION.— 
8
‘‘(A) IN GENERAL.—Subject to paragraph 
9
(3), the actions described in paragraph (1) by 
10
a manufacturer of a listed drug or reference 
11
product shall not be considered to be an unfair 
12
method of competition in or affecting commerce 
13
if— 
14
‘‘(i) the manufacturer demonstrates to 
15
the Commission or a district court of the 
16
United States, as applicable, by a prepon-
17
derance of the evidence in a proceeding ini-
18
tiated by the Commission under subsection 
19
(c)(1)(A), or in a suit brought under sub-
20
paragraph (B) or (C) of subsection (c)(1), 
21
that— 
22
‘‘(I) the manufacturer would 
23
have taken the actions regardless of 
24
whether a generic drug that ref-
25
21:44 Sep 20, 2019
H4398
8 
•HR 4398 IH
erences the listed drug or biosimilar 
1
biological product that references the 
2
reference product had already entered 
3
the market; and 
4
‘‘(II)(aa) with respect to a hard 
5
switch under paragraph (1)(A), the 
6
manufacturer took the action for rea-
7
sons relating to the safety risk to pa-
8
tients of the listed drug or reference 
9
product; 
10
‘‘(bb) with respect to an action 
11
described in item (aa) or (bb) of para-
12
graph (1)(A)(ii)(I), there is a supply 
13
disruption that— 
14
‘‘(AA) is outside of the con-
15
trol of the manufacturer; 
16
‘‘(BB) prevents the produc-
17
tion or distribution of the appli-
18
cable listed drug or reference 
19
product; and 
20
‘‘(CC) cannot be remedied 
21
by reasonable efforts; or 
22
‘‘(cc) with respect to a soft 
23
switch under paragraph (1)(B), the 
24
manufacturer had legitimate pro-com-
25
21:44 Sep 20, 2019
H4398
9 
•HR 4398 IH
petitive reasons, apart from the finan-
1
cial effects of reduced competition, to 
2
take the action. 
3
‘‘(B) RULE OF CONSTRUCTION.—Nothing 
4
in subparagraph (A) may be construed to limit 
5
the information that the Commission may oth-
6
erwise obtain in any proceeding or action insti-
7
tuted with respect to a violation of this section. 
8
‘‘(3) RESPONSE.—With respect to a justifica-
9
tion offered by a manufacturer under paragraph (2), 
10
the Commission may— 
11
‘‘(A) rebut any evidence presented by a 
12
manufacturer during that justification; or 
13
‘‘(B) establish by a preponderance of the 
14
evidence that, on balance, the pro-competitive 
15
benefits from the conduct described in subpara-
16
graph (A) or (B) of paragraph (1), as applica-
17
ble, do not outweigh any anticompetitive effects 
18
of the conduct, even in consideration of the jus-
19
tification so offered. 
20
‘‘(c) ENFORCEMENT.— 
21
‘‘(1) IN GENERAL.—If the Commission has rea-
22
son to believe that any manufacturer has violated, is 
23
violating, or is about to violate this section, the 
24
Commission may take any of the following actions: 
25
21:44 Sep 20, 2019
H4398
10 
•HR 4398 IH
‘‘(A) Institute a proceeding— 
1
‘‘(i) that, except as provided in para-
2
graph (2), complies with the requirements 
3
under section 5(b); and 
4
‘‘(ii) in which the Commission may 
5
impose on the manufacturer any penalty 
6
that the Commission may impose for a vio-
7
lation of section 5. 
8
‘‘(B) In the same manner and to the same 
9
extent as provided in section 13(b), bring suit 
10
in a district court of the United States to tem-
11
porarily enjoin the action of the manufacturer. 
12
‘‘(C) Bring suit in a district court of the 
13
United States, in which the Commission may 
14
seek— 
15
‘‘(i) to permanently enjoin the action 
16
of the manufacturer; 
17
‘‘(ii) any of the remedies described in 
18
paragraph (3); and 
19
‘‘(iii) any other equitable remedy, in-
20
cluding ancillary equitable relief. 
21
‘‘(2) JUDICIAL REVIEW.— 
22
‘‘(A) IN GENERAL.—Notwithstanding any 
23
provision of section 5, any manufacturer that is 
24
subject to a final order of the Commission that 
25
21:44 Sep 20, 2019
H4398
11 
•HR 4398 IH
is issued in a proceeding initiated under para-
1
graph (1)(A) may, not later than 30 days after 
2
the date on which the Commission issues the 
3
order, petition for review of the order in— 
4
‘‘(i) the United States Court of Ap-
5
peals for the District of Columbia Circuit; 
6
or 
7
‘‘(ii) the court of appeals of the 
8
United States for the circuit in which the 
9
ultimate parent entity of the manufacturer 
10
is incorporated. 
11
‘‘(B) TREATMENT OF FINDINGS.—In a re-
12
view of an order issued by the Commission con-
13
ducted by a court of appeals of the United 
14
States under subparagraph (A), the factual 
15
findings of the Commission shall be conclusive 
16
if those facts are supported by the evidence. 
17
‘‘(3) EQUITABLE REMEDIES.— 
18
‘‘(A) DISGORGEMENT.— 
19
‘‘(i) IN GENERAL.—In a suit brought 
20
under paragraph (1)(C), the Commission 
21
may seek, and the court may order, 
22
disgorgement of any unjust enrichment 
23
that a person obtained as a result of the 
24
violation that gives rise to the suit. 
25
21:44 Sep 20, 2019
H4398
12 
•HR 4398 IH
‘‘(ii) CALCULATION.—Any disgorge-
1
ment that is ordered with respect to a per-
2
son under clause (i) shall be offset by any 
3
amount of restitution ordered under sub-
4
paragraph (B). 
5
‘‘(iii) 
LIMITATIONS
PERIOD.—The 
6
Commission may seek disgorgement under 
7
this subparagraph not later than 5 years 
8
after the latest date on which the person 
9
from which the disgorgement is sought re-
10
ceives any unjust enrichment from the ef-
11
fects of the violation that gives rise to the 
12
suit in which the Commission seeks the 
13
disgorgement. 
14
‘‘(B) RESTITUTION.— 
15
‘‘(i) IN GENERAL.—In a suit brought 
16
under paragraph (1)(C), the Commission 
17
may seek, and the court may order, res-
18
titution with respect to the violation that 
19
gives rise to the suit. 
20
‘‘(ii) 
LIMITATIONS
PERIOD.—The 
21
Commission may seek restitution under 
22
this subparagraph not later than 5 years 
23
after the latest date on which the person 
24
from which the restitution is sought re-
25
21:44 Sep 20, 2019
H4398
13 
•HR 4398 IH
ceives any unjust enrichment from the ef-
1
fects of the violation that gives rise to the 
2
suit in which the Commission seeks the 
3
restitution. 
4
‘‘(4) RULES
OF
CONSTRUCTION.—Nothing in 
5
this subsection may be construed as— 
6
‘‘(A) requiring the Commission to bring a 
7
suit seeking a temporary injunction under para-
8
graph (1)(B) before bringing a suit seeking a 
9
permanent injunction under paragraph (1)(C); 
10
or 
11
‘‘(B) affecting any other authority of the 
12
Commission under this Act to seek relief or ob-
13
tain a remedy with respect to a violation of this 
14
Act.’’. 
15
(b) APPLICABILITY.—Section 27 of the Federal 
16
Trade Commission Act, as added by subsection (a), shall 
17
apply with respect to any— 
18
(1) conduct that occurs on or after the date of 
19
enactment of this Act; and 
20
(2) action or proceeding that is commenced on 
21
or after the date of enactment of this Act. 
22
(c) ANTITRUST LAWS.—Nothing in this section, or 
23
the amendments made by this section, shall modify, im-
24
pair, limit, or supersede the applicability of the antitrust 
25
21:44 Sep 20, 2019
H4398
14 
•HR 4398 IH
laws as defined in subsection (a) of the first section of 
1
the Clayton Act (15 U.S.C. 12(a)), and of section 5 of 
2
the Federal Trade Commission Act (15 U.S.C. 45) to the 
3
extent that it applies to unfair methods of competition. 
4
(d) RULEMAKING.—The Federal Trade Commission 
5
may issue rules under section 553 of title 5, United States 
6
Code, to carry out section 27 of the Federal Trade Com-
7
mission Act, as added by subsection (a), including by de-
8
fining any terms used in such section 27 (other than terms 
9
that are defined in subsection (a) of such section 27). 
10
Æ 
21:44 Sep 20, 2019
H4398
